Clinical Trials

Esophageal Neoplasms

NCT07389876 2026-02-05

G/GEJ

Recruiting

250 enrolled

Phase 1/2 Active not recruiting

Stomach Neoplasms

NCT06710847 2026-02-02

SYLVER

14 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06283238 2026-01-29

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

Withdrawn

GastroEsophageal Cancer

NCT05166239 2026-01-23

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Phase 2 Completed

66 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT07339488 2026-01-14

ILDR-03

43 enrolled

Esophageal Squamous Cell Carcinoma

NCT07279077 2025-12-26

MODIFI-L

38 enrolled

Colonic Neoplasms

NCT07282184 2025-12-18

Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention

Phase 1/2 Recruiting

144 enrolled

Carcinoma, Hepatocellular

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

300 enrolled

Biliary Tract Neoplasms

NCT06248554 2025-12-02

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Phase NA Recruiting

200 enrolled

Carcinoma, Hepatocellular

NCT06154538 2025-11-28

Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer

170 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Locally Advanced Colorectal Carcinoma

NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Phase 1 Terminated

17 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06496373 2025-11-17

Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

20 enrolled

Pancreatic Neoplasms

NCT07230301 2025-11-17

Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions

20 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Pancreatic Cancer Metastatic

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT07007182 2025-09-05

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT07157306 2025-09-05

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

35 enrolled

Phase 4 Not yet recruiting

Carcinoma, Hepatocellular

NCT07149181 2025-08-29

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

1,000 enrolled

Phase 4 Not yet recruiting

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07132528 2025-08-20

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

1,000 enrolled

Gastric / Gastroesophageal Junction Adenocarcinoma

NCT07100405 2025-08-17

TASK-01-RW

Recruiting

50 enrolled

Carcinoma, Hepatocellular

NCT06740370 2025-08-14

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

Phase NA Recruiting

32 enrolled

Carcinoma, Hepatocellular

NCT06980350 2025-07-29

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

Completed

156 enrolled

Colorectal Neoplasms

NCT07064668 2025-07-15

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

300 enrolled

Carcinoma, Hepatocellular

NCT07040098 2025-06-26

STELLARIII

228 enrolled

Phase 1 Not yet recruiting

Locally Advanced Rectal Cancer (LARC)

NCT07034118 2025-06-24

Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study

23 enrolled

Esophageal Neoplasms

NCT07009600 2025-06-06

Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

Completed

124 enrolled

Phase 1 Active not recruiting

Stomach Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

39 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT06991907 2025-05-28

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety

Phase NA Completed

80 enrolled

Carcinoma, Hepatocellular

NCT06957977 2025-05-06

A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer

42 enrolled

Stomach Neoplasms

NCT06685887 2025-04-11

A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

34 enrolled

Stomach Neoplasms

NCT06900686 2025-03-28

Clinical Application of PD-1 Inhibitor in Colorectal Cancer for Improving Survival

Completed

458 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colonic Neoplasms, Rectal Neoplasms

NCT06890624 2025-03-27

OPTICAL-3

138 enrolled

Colonic Neoplasms

NCT05713994 2025-03-25

CCGLC-001

Recruiting

300 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Not yet recruiting

600 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Phase 2 Active not recruiting

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT05491616 2025-02-13

SANO-3

77 enrolled

Esophageal Neoplasms

NCT05497453 2025-02-03

MYCHELANGELO I

Phase 1/2 Terminated

24 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05937438 2025-01-29

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Phase 1/2 Recruiting

70 enrolled

Esophageal Neoplasms

NCT03695952 2025-01-28

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

Active not recruiting

100 enrolled

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT06622031 2025-01-13

TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

Phase NA Recruiting

42 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT06708650 2024-11-27

Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma

50 enrolled

Carcinoma, Hepatocellular

NCT06632106 2024-10-08

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Active not recruiting

97 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT04230759 2024-09-19

RADIANCE

180 enrolled